Item 1.
Biofrontera AG
(b) | Address of issuer’s principal executive offices: |
Hemmelrather Weg 201, 51377 Leverkusen, Germany
Item 2.
(a) | Name of person filing: |
This Schedule 13G is being jointly filed by (i) Maruho Deutschland GmbH (“Maruho Germany”) and (ii) Maruho Co., Ltd. (“Maruho Japan”, and together with Maruho Germany, the “Reporting Persons”). Maruho Germany directly beneficially owns the Ordinary Shares covered by this Schedule 13G, but is a wholly owned subsidiary of Maruho Japan.
The Reporting Persons have entered into a Joint Filing Agreement, dated February 1, 2019, a copy of which is attached as Exhibit 99.1 to this Schedule 13G, pursuant to which the Reporting Persons agreed to file this Schedule 13G and any subsequent amendments hereto.
(b) | Address or principal business office or, if none, residence: |
Maruho Japan:1-5-22 Nakatsu,Kita-ku, Osaka, Japan
Maruho Germany: Hemmelrather Weg 201, 51377 Leverkusen, Germany
Maruho Japan and Maruho Germany are organized under the laws of Japan and Germany, respectively.
(d) | Title of class of securities: |
Ordinary Shares
The Ordinary Shares have no CUSIP number. The CUSIP number for the ADSs, each representing two Ordinary Shares, is 09075G105.
Item 3. If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:
(a) | ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
(b) | ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
(c) | ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |